Pilot Study of Entacapone for Methamphetamine Abuse
| Status: | Completed |
|---|---|
| Conditions: | Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 45 |
| Updated: | 10/14/2017 |
| Start Date: | June 2014 |
| End Date: | June 2016 |
Pilot Study of the Dose Response of Entacapone on Methamphetamine Induced Interest, Mood Elevation, and Reward
Addiction to methamphetamine is a serious health problem. There are no medications that a
doctor can give someone to help them stop using methamphetamine. Entacapone (Comtan©) is a
medication that could help people addicted to methamphetamine.
This study will see how entacapone works in healthy people who are given methamphetamine. We
think that the study drug will be well tolerated, and that it will prevent some of the
effects of methamphetamine that make it so addictive. We also want to see how differences in
people's genes may cause differences in the ways the study drug and methamphetamine work for
them.
The study has six total visits. The first visit is for screening. Tests and procedures will
make sure it is safe for subjects to participate.
The second visit is a familiarization day. Subjects will receive methamphetamine, but no
entacapone. This is done to make sure they can tolerate the drug and recognize its effects
before being given a second drug on the same day. Subjects will take surveys and computer
tests to see how the medications change mood, thinking, and liking the drug.
The final four visits are the actual study days. Subjects will be randomly assigned (like the
flip of a coin) to the different ways to get either 1) study medication or placebo (placebo
contains no active study medication) and then 2) methamphetamine or placebo. Subjects will be
in all four groups during the study, which means that each day a subject will get a different
group.
doctor can give someone to help them stop using methamphetamine. Entacapone (Comtan©) is a
medication that could help people addicted to methamphetamine.
This study will see how entacapone works in healthy people who are given methamphetamine. We
think that the study drug will be well tolerated, and that it will prevent some of the
effects of methamphetamine that make it so addictive. We also want to see how differences in
people's genes may cause differences in the ways the study drug and methamphetamine work for
them.
The study has six total visits. The first visit is for screening. Tests and procedures will
make sure it is safe for subjects to participate.
The second visit is a familiarization day. Subjects will receive methamphetamine, but no
entacapone. This is done to make sure they can tolerate the drug and recognize its effects
before being given a second drug on the same day. Subjects will take surveys and computer
tests to see how the medications change mood, thinking, and liking the drug.
The final four visits are the actual study days. Subjects will be randomly assigned (like the
flip of a coin) to the different ways to get either 1) study medication or placebo (placebo
contains no active study medication) and then 2) methamphetamine or placebo. Subjects will be
in all four groups during the study, which means that each day a subject will get a different
group.
Inclusion Criteria:
- No history of pre-existing physical (including cardiovascular) illness
- No history of drug abuse or dependence
- Ability to read and write English
- Have had at least one exposure to a stimulant (e.g. cocaine, methamphetamine, ecstasy,
methylphenidate or any medication in the stimulant class) in their lifetime
Exclusion Criteria:
- Pregnant
- Taking any psychotropic medication
- Meeting DSM-IV criteria for active substance abuse or dependence
- On any stimulant medication
- History or current hypertension (BP > 140/90 mm Hg) or systolic hypotension (SBP < 90
mm Hg)
- Subjects with resting pulse rate > 90/min
- Any active medical illness
- Family history of abnormal heart rhythms, or sudden cardiac death
- Subjects who anticipate they may require the emergent use of epinephrine (such as an
Epi-Pen®) for the treatment of severe allergic reactions
We found this trial at
1
site
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
Portland, Oregon 97239
503 494-8311
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
Click here to add this to my saved trials
